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Identity 
Other names: HIRS-1 




Insulin receptor substrate 1 (IRS1) was the first IRS 
family member to be identified and cloned (Sun et al., 
1991).  
The entire gene is about 68,4 kb and contains 2 exons 
(start: 227596033 and end: 227664745; orientation: 
minus strand). The cDNA contains 8743 bp. 
Protein 
Description 
IRS1 belongs to the insulin receptor substrate (IRS) 
protein family, these proteins are characterized by the 
presence of a pleckstrin homology (PH) domain and a 
phosphotyrosine binding (PTB) domain (figure 1).  
The PH domain contributes to protein-protein binding 
and facilitates the recruitment of IRS proteins by cell 
membrane receptors. The PTB domain is actived by 




IRS1 is predominantly found in the cytoplasm. Nuclear 
localization may occur in some cell types and under 
specific stimuli. 
Function 
IRS1 is an intracellular signaling adaptor protein that 
integrates and coordinates numerous biologically key 
extracellular signals within the cell. First identified as a 
signaling intermediate of the insulin receptor (IR), it is 
now clear that IRS1 is the main substrate of the insulin-




Figure 1. Schematic structure of IRS1. Interaction domains of IRS1: pleckstrin homology (PH) domain (purple), phosphotyrosine 
binding (PTB) domain (green) and effector binding sites (including PI3K, Grb2 and SHP2) are indicated. 






Atlas Genet Cytogenet Oncol Haematol. 2013; 17(9)  595 
 
Figure 2. IRS1 signaling pathway. IRS1 is recruited by its PH/PTB domains and phosphorylated in tyrosine residues (pY) by upstream 
tyrosine kinase receptors. Tyrosine phosphorylated IRS1 binds to signaling effectors and activates signaling cascades, regulating several 
biological processes, including proliferation and survival. 
 
 
IRS1 contains multiple tyrosine phosphorylation sites, 
which during insulin stimulation are phosphorylated 
and act as docking sites for multiple SH2-containing 
proteins including PI3K, Grb2, Nck, Crk, Fyn, Syp and 
SHP2 (Mardilovich et al., 2009).  
The two best-studied being the PI3K/Akt/mTOR and 
the MAPK pathway, which includes the ERK protein 
(figure 2) (Mardilovich et al., 2009). IRS1 has no 
intrinsic kinase activity and requires upstream 
activators, however many studies have shown that this 
signaling adaptor is in itself oncogenic and can induce 
malignant transformation (Dearth et al., 2007). 
More recently, nuclear localization of IRS1 was 
observed in cells expressing SV40 T antigen, 
fibroblasts under IGF1 stimulation, hepatocytes, 32D 
cells and others.  
Several nuclear functions have been attributed to IRS1, 
including DNA repair fidelity, transcriptional activity 
and cell growth, which contributes to tumor 
development and progression (Reiss et al., 2011). 
Homology 
IRS1 shares high homology in its N-termini with  
the other members of the IRS proteins family.  
IRS1 also shares a high homology among different 
species (table 1). 
Mutations 
Note 
Mutations in this gene are associated with type II 
diabetes and susceptibility to insulin resistance (Kovacs 





IRS1 was identified as a binding partner of BCR-ABL 
protein and found to be involved in the activation of the 
PI3K/Akt/mTOR and MAPK signaling pathway in the 
BCR-ABL network (Traina et al., 2003). 
In BCR-ABL positive leukemia cells, IRS1 silencing 
resulted in decreased cell proliferation and 
clonogenicity (Machado-Neto et al., 2011). 
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Table 1. Comparative identity of human IRS1 with other species. Source: HomoloGene. 
 
In addition, IRS1 expression was found to be 
negatively correlated with survival in patients with Ph+ 
acute lymphosblastic leukemia, regardless of age and 
white blood cell count at diagnosis (Juric et al., 2007). 
Breast cancer 
Note 
In breast cancer tumors, IRS1 has been described as 
constitutively activated and its expression has been 
correlated with poor differentiation and positive lymph 
node status (Chang et al., 2002; Lee et al., 1999; Koda 
et al., 2005). High levels of IRS1 were associated with 
lower disease-free survival and positively correlated 
with proliferation in estrogen receptor (ER) positive 
breast cancer tumors (Rocha et al., 1997). In ER 
positive breast cancer cells, IRS1 silencing promoted 
apoptosis and increased the sensibility to chemotherapy 
(Cesarone et al., 2006). 
Hepatocellular carcinoma 
Note 
IRS1 was found overexpressed in 80% of 
hepatocellular carcinoma (HCC) when compared with 
adjacent HCC-free tissue (Cantarini et al., 2006). In 
vitro experiments provided evidence that IRS1 
overexpression was able to promote malignant 
transformation of hepatocytes (Tanaka et al., 1997). 
Lung cancer 
Note 
Han et al. reported a downregulation of IRS1 in non-
small cell lung cancer (NSCLC) and suggested that loss 
of IRS1 might be an early event in NSCLC 
development (Han et al., 2006). 
Medulloblastoma 
Note 
Abundant IRS1 expression was found in 
medulloblastoma cell lines and medulloblastoma 
biopsies. Nuclear translocation of IRS1 was observed 
in all cell lines and primary samples in the presence of  
 
 
the JC virus T antigen (Del Valle et al., 2002). 
Mesothelioma 
Note 
Up-regulation of IRS1 was found in mesothelioma 
samples and may contribute to malignant pleural 
mesothelioma tumorigenesis by IGF1-induced cell 
proliferation (Hoang et al., 2004). 
Ovarian cancer 
Note 
The majority of malignant epithelial ovarian tumors 
showed IRS1 overexpression when compared with 
normal ovarian tissue, suggesting a correlation between 
IRS1 expression and cancer phenotype. The same study 
suggested that IRS1 is an important growth-regulatory 
protein and may be a possible target in ovarian cancer 
(Ravikumar et al., 2007). 
Pancreatic cancer 
Note 
IRS1 was highly expressed in 43% of pancreatic cancer 
samples when compared with normal pancreas samples 
(Bergmann et al., 1996). 
Prostate cancer 
Note 
High expression of IRS1 was correlated with high 
expression of IGF1R in both benign and malignant 
prostate samples (Hellawell et al., 2002), but IRS1 
expression did not differ among these samples. In 
prostate cancer cells, IRS1 silencing plus rapamycin 
treatment synergistically antagonized the activation of 
mTOR and induced tumor suppression in vivo, through 
inhibition of proliferation and induction of apoptosis 
(Oliveira et al., 2008). 
Endometrial cancer 
Note 
IRS1 activation was significantly elevated in patients 
with endometrial cancer (EC) compared to those  
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without EC and was associated with aggressive 
features. In addition, Wang et al. suggested that the 
inhibition of the IR/IRS1/PI3K/Akt pathway could be 
used as preventive and therapeutic strategies for EC 
(Wang et al., 2012). 
Colorectal cancer 
Note 
Esposito et al. reported that IRS1 was found highly 
expressed in adenomas of familial adenomatous 
polyposis patients, relative to paired normal mucosa, 
and in metastasized colorectal tumors compared with 
primary colorectal cancer (CRC) and colonic 
epithelium (Esposito et al., 2012). The authors also 
related that IRS1 staining was associated with high 
expressions of Ki67, p53, and β-catenin, suggesting 
that IRS1 is modulated according to CRC 
differentiation and plays a role in CRC progression and 
metastasis (Esposito et al., 2012). 
To be noted 
Note 
Animal model: IRS1 knockout mice were born alive 
but were showed retarded embryonic and postnatal 
growth (approximately 30% smaller than wild type 
littermates), and also had resistance to the glucose-
lowering effects of insulin, IGF1 and IGF2 (Tamemoto 
et al., 1994). 
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